New hope for kids with rare autoimmune disease: drug aims to stop relapses
NCT ID NCT05346354
First seen Nov 12, 2025 · Last updated May 24, 2026 · Updated 29 times
Summary
This study tests a medicine called ravulizumab in children and teens (ages 2 to 17) with a rare disease called NMOSD that causes inflammation in the brain and spinal cord. The goal is to see if the drug can reduce the number of attacks and slow down disability. Participants receive the drug through an IV and are followed for about a year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGWashington D.C., District of Columbia, 20010, United States
-
Research Site
RECRUITINGMiami, Florida, 33136, United States
-
Research Site
RECRUITINGBoston, Massachusetts, 02114, United States
-
Research Site
WITHDRAWNSt Louis, Missouri, 63110, United States
-
Research Site
RECRUITINGDurham, North Carolina, 27705, United States
-
Research Site
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
-
Research Site
RECRUITINGEdmonton, Alberta, T6G 1C9, Canada
-
Research Site
RECRUITINGToronto, Ontario, M5G 1X8, Canada
-
Research Site
RECRUITINGMontreal, Quebec, H3T1C5, Canada
-
Research Site
RECRUITINGLe Kremlin-Bicêtre, 94270, France
-
Research Site
RECRUITINGMarseille, 13005, France
-
Research Site
RECRUITINGMontpellier, 34295, France
-
Research Site
WITHDRAWNBochum, 44791, Germany
-
Research Site
WITHDRAWNGiessen, 35392, Germany
-
Research Site
WITHDRAWNCatania, 95123, Italy
-
Research Site
RECRUITINGChieti, 66013, Italy
-
Research Site
RECRUITINGGallarate, 21013, Italy
-
Research Site
RECRUITINGRoma, 00165, Italy
-
Research Site
RECRUITINGYokohama, 232-0024, Japan
-
Research Site
RECRUITINGGoyang-si, 10408, South Korea
-
Research Site
RECRUITINGEsplugues de Llobregat, 8950, Spain
Conditions
Explore the condition pages connected to this study.